Antitumor effects and pharmacological interaction of Xiao-Chai-Hu-Tang (Sho-Saiko-To) and interleukin 2 in murine renal cell carcinoma

Keio Journal of Medicine

Volumn 46, Issue 3, 1997, Pages 132-137

  Huang, Yongping ^a   Marumo, Ken ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Interleukin 2; Interleukin 6; Renal cell carcinoma; Sino Japanese medicine; Xiao Chai Hu Tang

Indexed keywords

INTERLEUKIN 2; XIAO CHAI HU TANG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG POTENTIATION; KIDNEY CARCINOMA; MOUSE; NONHUMAN;

EID: 0030751053     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.46.132     Document Type: Article

References (25)

1. deKernion JB, Berry D: The diagnosis and treatment of renal cell carcinoma. Cancer 1980; 45 (suppl7): 1947-1956
2. deKernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978; 120: 148-152
3. Patel NP, Lavengood RW: Renal cell carcinoma: natural history and results of treatment. J Urol 1978; 119: 722-726
4. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976; 193: 1007-1008
5. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897
6. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905
7. Marumo K, Muraki J, Ueno M, Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H: Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 1989; 33: 219-225
8. Marumoto M, Maeda T, Kato M, Hayashi E: Anti-inflammatory action of Sho-saiko-toh. Proc Symp Soc Wakan-Yaku 1983; 16: 153-157 (in Japanese)
9. Mizoguchi Y, Sakagami Y, Okura Y, Yamamoto S, Morisawa S: Effects of Sho-saiko-to (TJ-9) in hepatitis patients and on the metabolism of arachidonic acid. In: Hosoya E, Yamamura Y, eds, Recent Advances in the Pharmacology of Kampo (Japanese Herbal) Medicines, International Congress Series; 854, Amsterdam, Elsevier Science Publishers B. V., 1988; 396-404
10. Ito H, Shimura K: Studies on antitumor activity of traditional Chinese medicines (1). Gan To Kagakuryoho (Jpn J Cancer Chemother) 1985; 12: 2145-2148 (in Japanese)
11. Murphy GP, Hrushesky WJ: Murine renal cell carcinoma. J Natl Cancer Inst 1973; 50: 1013-1025
12. Yamashiki M, Kosaka Y, Nishimura A, Takase K, Ichida F: Efficacy of a herbal medicine "sho-saiko-to" on the improvement of impaired cytokine production of peripheral blood mononuclear cells in patients with chronic viral hepatitis. J Clin Lab Immunol 1992; 37: 111-121
13. Yamaoka Y, Kawakita T, Kaneko M, Nomoto K: A polysaccharide fraction of Shosaiko-to active in augmentation of natural killer activity by oral administration. Biol Pharm Bull 1995; 18: 846-849
14. Cunliffe-Beamer TL, Les EP: The laboratory mouse. In: Poole TB, ed, The UFAW Handbook on the Care and Management of Laboratory Animals, 6th Ed, New York, Churchill Livingstone Inc, 1987; 275-308
15. Murakami K, Okajima K, Sakata K, Takatsuki K: A possible mechanism of interstitial pneumonia during interferon therapy with sho-saiko-to. Nippon Kyobu Shikkan Gakkai Zasshi (Jpn J Thoracic Diseases) 1995; 33: 389-394 (in Japanese)
16. Elias JA, Jimenez SA, Freundlich B: Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am Rev Respir Dis 1987; 135: 62-65
17. Tomioka H: Kampo-Hozai induced pneumonitis. Saishin Igaku 1992; 47: 1342-1348 (in Japanese)
18. Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K: Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon γ production. J Immunol 1983; 130: 988-992
19. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-76
20. Andus T, Geiger T, Hirano T, Northoff H, Ganter U, Bauer J, Kishimoto T, Heinrich PC: Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-β 2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett 1987; 221: 18-22
21. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M: Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1987; 84: 9035-9039
22. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwao K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85
23. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250: 607-610
24. Blay JY, Negrier S, Combaret V, Attali S, Goulot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322
25. Matsuura K, Kawakita T, Nakai S, Saito Y, Suzuki A, Nomoto K: Role of B-lymphocytes in the immunopharmacological effects of a traditional Chinese medicine, xiao-chai-hu-tang (Shosaikoto). Int J Immunopharmacol 1993; 15: 237-243